Spark Therapeutics, Inc.
Spark Therapeutics, Inc. (SPARK): 13 pipeline candidates · ~72 mo cash runway · 19 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
71.9 months
D/E 1.03 · 0% dilution
Lead: Approved
13 candidates
N/A
N/A
A transparent, data-derived signal for Spark Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$258.6M
Quarterly Burn
$18.4M
Runway
71.9 mo
Revenue
$22.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| aav2-hrpe65v2 | Phase 3 |
| extended-release injectable naltrexone | — |
| fidanacogene elaparvovec | Phase 3 |
| lofexidine | — |
| luxturna | Approved |
| spk-3006 | Phase 1 |
| spk-7001 | Phase 1/Phase 2 |
| spk-8011 | Phase 1/Phase 2 |
| spk-8016 | Phase 1/Phase 2 |
| spk-9001 | Phase 1/Phase 2 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Spark Therapeutics, Inc.'s pipeline?
Spark Therapeutics, Inc. (SPARK) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Spark Therapeutics, Inc.'s lead drug candidate?
Spark Therapeutics, Inc.'s most advanced tracked candidate is aav2-hrpe65v2 (Phase 3) for Inherited Retinal Dystrophy Due to RPE65 Mutations; Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy.
What is Spark Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Spark Therapeutics, Inc. has approximately 71.9 months of cash runway.
Who is the CEO of Spark Therapeutics, Inc.?
Jeffrey D. Marrazzo is the chief executive officer of Spark Therapeutics, Inc. (SPARK).
Get the full picture on Spark Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.